Publications by authors named "J Hotton"
: The aim is to propose a model for predicting occult paraaortic lymph node (PALN) involvement in locally advanced cervical cancer (LACC) patients by including parameters such as reconstruction detection technology (use of time-of-flight) and parameters related to the primary tumor. This model will then be compared with the scores used in routine clinical practice; : This retrospective observational cohort study included patients diagnosed with LACC who underwent F-FDG PET/CT prior to PALN surgical staging between February 2012 and May 2020. The following parameters were collected on PET/CT: tumor SUVmax, tumor MTV, number of common and distal pelvic node involvements.
View Article and Find Full Text PDFArticle Synopsis
- * Men exhibited higher rates of 90-day reoperation (21.2% vs. 18.8%) and mortality (1.2% vs. 0.9%) after surgery, although women had a higher 90-day mortality rate for bladder cancer.
- * The study emphasizes the importance of addressing gender disparities in access to cancer surgery and improving outcomes for both men and women.
Article Synopsis
- Optimizations in immunotherapy for Triple-negative breast cancer (TNBC) show promise, particularly in targeting galectin-9 (Gal-9) after radiotherapy.
- In TNBC patients receiving neoadjuvant radiotherapy, higher Gal-9 levels were observed in non-responders compared to baseline, indicating a potential link between Gal-9 expression and treatment response.
- A study in mice showed that targeting Gal-9 with an antibody led to reduced tumor growth only in those injected with irradiated cancer cells, suggesting Gal-9's potential as a biomarker and therapeutic target in TNBC.
Importance: With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking.
Objective: To assess the risk of pregnancy-, fetal-, and/or newborn-related adverse outcomes associated with exposure to ICIs compared with exposure to other anticancer agents.
Design, Setting, And Participants: In this cohort study, all reports mentioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) used for a cancer indication registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted.
Article Synopsis
- Many people with breast cancer already have other health issues and are taking medications before they are diagnosed.
- A study looked at 235,368 French women with breast cancer to see how their medications affected their survival.
- They found some medications that might help survival and some that might hurt it, and the full results can be checked online for more details.